secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-152145
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma triggers $250M milestone after positive daraxonrasib Phase 3 results
--------------------------------------------------------------------------------

- Revolution Medicines' RASolute 302 trial met primary and key secondary endpoints (PFS and OS) in metastatic PDAC.
- Royalty Pharma funded $250M upfront; positive data triggers additional $250M milestone, total $500M funded.
- Royalty Pharma now earns 4.55% tiered royalty on daraxonrasib sales up to $2B, lower rates above $2B.
- Additional $750M synthetic royalty available upon FDA approval and other milestones; first $250M on approval.
- Senior secured loan of up to $750M available; first $250M tranche must be drawn after FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/0001193125-26-152145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-152145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer